Using Stock Price Movements to Estimate the Harm from Anticompetitive Drug Patent Litigation Settlements

Keith M. Drake and Thomas McGuire

No 33196, NBER Working Papers from National Bureau of Economic Research, Inc

Abstract: Drug patent litigation settlements containing brand-to-generic “reverse payments” are a decades old antitrust concern that has been estimated to cost drug purchasers billions of dollars per year. Most estimates of the harm rely on the Federal Trade Commission’s calculation that such payments delay generic entry by 17 months, which is based on 15-20-year-old data. This paper takes a different approach, using stock price movements to quantify the harm. Costs to purchasers from an anticompetitive agreement are approximately equal to the brand firm’s increase in profits. If new profits are capitalized into stock prices, the change in value upon a settlement announcement can be used to estimate the new profit flows. We assembled a list of 64 settlements announced during 2014-2023. Although the announcements did not describe explicit forms of reverse payment, 16 announcements described terms that may transfer value to the generic firms. We classified these settlements as having an indication of reverse payment. Consistent with prior research, settlement announcements with no indication of reverse payment had no significant effect on the stock prices of brand firms implying that they tended to meet traders’ expectations. Stock prices increased by approximately 3.5%, on average, after settlements with indication of reverse payment, implying they increased brand profits by delaying generic entry. We estimate that these increases correspond to a total increase in purchaser spending of $2.9-$3.0 billion per year. Because our sample is not a full census of settlements, the industry-wide increase in spending may be closer to $7 billion per year.

JEL-codes: I11 L41 (search for similar items in EconPapers)
Date: 2024-11
New Economics Papers: this item is included in nep-ind, nep-ipr and nep-reg
Note: EH IO
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.nber.org/papers/w33196.pdf (application/pdf)
Access to the full text is generally limited to series subscribers, however if the top level domain of the client browser is in a developing country or transition economy free access is provided. More information about subscriptions and free access is available at http://www.nber.org/wwphelp.html. Free access is also available to older working papers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:33196

Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w33196
The price is Paper copy available by mail.

Access Statistics for this paper

More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by (wpc@nber.org).